<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05360000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q07869</UniProt_ID>
  <Seq_Length>468</Seq_Length>
  <Molecule_Weight>52225</Molecule_Weight>
  <KEGG_ID>hsa:5465</KEGG_ID>
  <Orthology_ID>K07294</Orthology_ID>
  <EBI_ID>EBI-78615</EBI_ID>
  <Function_Summary>Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety (By similarity). Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 1 group C member 1</Alias>
      <Alias>PPAR-alpha</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>A ligand-dependent receptor found in the nucleus of the cell.</Detail>
      <Keyword>Ligand-dependent nuclear receptor activity</Keyword>
      <Ontology_ID>GO:0004879</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.</Detail>
      <Keyword>Drug binding</Keyword>
      <Ontology_ID>GO:0008144</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a ubiquitin conjugating enzyme, any of the E2 proteins.</Detail>
      <Keyword>Ubiquitin conjugating enzyme binding</Keyword>
      <Ontology_ID>GO:0031624</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>395</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>227</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>162</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>127</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>268</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>409</Position>
      <Original>Arg</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that reduces appetite.</Detail>
      <Keyword>Negative regulation of appetite</Keyword>
      <Ontology_ID>GO:0032099</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency or rate of receptor biosynthesis. Receptor biosynthesis is the collection of chemical reactions and pathways resulting in the formation of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Negative regulation of receptor biosynthetic process</Keyword>
      <Ontology_ID>GO:0010871</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.</Detail>
      <Keyword>Negative regulation of glycolysis</Keyword>
      <Ontology_ID>GO:0045820</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of lipid transport by activating or increasing the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Regulation of lipid transport by positive regulation of transcription from an RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0072369</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of glycolysis by activating or increasing the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Regulation of glycolysis by positive regulation of transcription from an RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0072363</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.</Detail>
      <Keyword>Fatty acid transport</Keyword>
      <Ontology_ID>GO:0015908</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of a cellular ketone metabolic process by activating or increasing the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Regulation of cellular ketone metabolic process by positive regulation of transcription from an RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0072366</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.</Detail>
      <Keyword>Fatty acid metabolic process</Keyword>
      <Ontology_ID>GO:0006631</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of fatty acid beta-oxidation.</Detail>
      <Keyword>Positive regulation of fatty acid beta-oxidation</Keyword>
      <Ontology_ID>GO:0032000</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.</Detail>
      <Keyword>Negative regulation of sequestering of triglyceride</Keyword>
      <Ontology_ID>GO:0010891</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.</Detail>
      <Keyword>Negative regulation of macrophage derived foam cell differentiation</Keyword>
      <Ontology_ID>GO:0010745</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Negative regulation of cholesterol storage</Keyword>
      <Ontology_ID>GO:0010887</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY</Protein_Seq>
    <DNA_Seq>GCGCCGCCTCCTTCGGCGTTCGCCCCACGGACCGGCAGGCGGCGGACCGCGGCCCAGGCTGAAGCTCAGGGCCCTGTCTGCTCTGTGGACTCAACAGTTTGTGGCAAGACAAGCTCAGAACTGAGAAGCTGTCACCACAGTAGCTTGGAGCTCGGCGGCACAACCAGCACCATCTGGTCGCGATGGTGGACACGGAAAGCCCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAGAGCCCGTTATCTGAAGAGTTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCCATCGGCGAGGATAGTTCTGGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGTCCTGGCTCAGATGGCTCGGTCATCACGGACACGCTTTCACCAGCTTCGAGCCCCTCCTCGGTGACTTATCCTGTGGTCCCCGGCAGCGTGGACGAGTCTCCCAGTGGAGCATTGAACATCGAATGTAGAATCTGCGGGGACAAGGCCTCAGGCTATCATTACGGAGTCCACGCGTGTGAAGGCTGCAAGGGCTTCTTTCGGCGAACGATTCGACTCAAGCTGGTGTATGACAAGTGCGACCGCAGCTGCAAGATCCAGAAAAAGAACAGAAACAAATGCCAGTATTGTCGATTTCACAAGTGCCTTTCTGTCGGGATGTCACACAACGCGATTCGTTTTGGACGAATGCCAAGATCTGAGAAAGCAAAACTGAAAGCAGAAATTCTTACCTGTGAACATGACATAGAAGATTCTGAAACTGCAGATCTCAAATCTCTGGCCAAGAGAATCTACGAGGCCTACTTGAAGAACTTCAACATGAACAAGGTCAAAGCCCGGGTCATCCTCTCAGGAAAGGCCAGTAACAATCCACCTTTTGTCATACATGATATGGAGACACTGTGTATGGCTGAGAAGACGCTGGTGGCCAAGCTGGTGGCCAATGGCATCCAGAACAAGGAGGCGGAGGTCCGCATCTTTCACTGCTGCCAGTGCACGTCAGTGGAGACCGTCACGGAGCTCACGGAATTCGCCAAGGCCATCCCAGGCTTCGCAAACTTGGACCTGAACGATCAAGTGACATTGCTAAAATACGGAGTTTATGAGGCCATATTCGCCATGCTGTCTTCTGTGATGAACAAAGACGGGATGCTGGTAGCGTATGGAAATGGGTTTATAACTCGTGAATTCCTAAAAAGCCTAAGGAAACCGTTCTGTGATATCATGGAACCCAAGTTTGATTTTGCCATGAAGTTCAATGCACTGGAACTGGATGACAGTGATATCTCCCTTTTTGTGGCTGCTATCATTTGCTGTGGAGATCGTCCTGGCCTTCTAAACGTAGGACACATTGAAAAAATGCAGGAGGGTATTGTACATGTGCTCAGACTCCACCTGCAGAGCAACCACCCGGACGATATCTTTCTCTTCCCAAAACTTCTTCAAAAAATGGCAGACCTCCGGCAGCTGGTGACGGAGCATGCGCAGCTGGTGCAGATCATCAAGAAGACGGAGTCGGATGCTGCGCTGCACCCGCTACTGCAGGAGATCTACAGGGACATGTACTGAGTTCCTTCAGATCAGCCACACCTTTTCCAGGAGTTCTGAAGCTGACAGCACTACAAAGGAGACGGGGGAGCAGCACGATTTTGCACAAATATCCACCACTTTAACCTTAGAGCTTGGACAGTCTGAGCTGTAGGTAACCGGCATATTATTCCATATCTTTGTTTTAACCAGTACTTCTAAGAGCATAGAACTCAAATGCTGGGGGTAGGTGGCTAATCTCAGGACTGGGAAGATTACGGCGAATTATGCTCAATGGTCTGATTTTAACTCACCCGATGTTAATCAATGCACATTGCTTTAGATCACATTCGTGATTTACCATTTAATTAACTGGTAACCTCAAAATTCGTGGCCTGTCTTCCCATTCACCCCGCTTTTGACTATTGTGCTCCTTTATAATTCTGAAAACTAATCAGCACTTTTTAACAATGTTTATAATCCTATAAGTCTAGATGTATCCAAAGGTGAAGTATGTAAAAAGCAGCAAAATATTTATTTCAAAGACTTCACTTCTGTTTCCTGAATCTAAAGAAAGACAACATGCTGCTTTTTAATCATAGGATGGAGAATTTTAAAGAACTGTTTGGGCCAGGCACAGTCGCTCATACTTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACAAGGTCAGCAGATCGAGACCATCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCGGGTGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAAGCTGAGGCAGGAGAATTGCTTGAACCAGGGAGTTGGAGGTTGCAGTGAGCTAAGACTGCACCACTGCACTCCAGCCTGGTGACAGAACGAGACTCTGTCTTAAAAACAAACAAACAAAAAAAAAATCTGTTAGATAAGCTATCAAAATGCAGCTGTTGTTTTGTTTTTGGCTCACTGTTTTCGTGGTTGTAACTAATATGTGGAAAGGCCCATTTCCAGGTTTGCGTAGAAGAGCCCAGAAAACAGAGTCTCAAGACCCCCGCTCTGGACTGTCATAAGCTAGCACCCGTGGTAAGCGGGACGAGACAAGCTCCCGAAGCCCGCCAGCTTCCTGCTCCACTCAGCTCCGTCCAGTCAACCTGAACCCACCCAGTCCAGCTGTCTGTGGGAATGGTGGTGTTCTTAGGGACAGACTGACACCTTACTTGTCAGTGTTCCTCCGGGCCCCATTTGGCAGCTCCCGTATCTTTTGTTATGTTGCTTTTAAAGATATGATGTTTTATTGTTTTAACTCTTGGTGACAGTAGATGCTCTCTGGAGCGCAGACGAGGCACATGTGTCTTCATAGCCTGGGCTGGGTGGGAGCCAGTCACCCTGCGGATCGAGAGAGGGGGTAGAGTCTTCTTCAAATGGCAGTTTTACTTCAAATGGCAGATTTCACAAGAGTTGGTTATTTTTTACAATGGTTTAGGTTGTTAAGTCTCCTTTGTATGTAAGGTAGTTTTTTCAACATCTAAAATTTTTGTTTTAGCCTTCAAAACCAACTTACCAACCTCAGTCCAGCTGGGAAGGCAGCGTTGATTATGGTAGTTTGTCAAGAATATATGGACCTGGAAACACTTTCTCTCTCTGTCCACCTGGTAGATAAATTGTCCTGTTGAGAATTTTTAGATCTGGACTGGAACTGCCAGGACCACCGCCTCCAGGGAGTCGCTGGGCACCTGGAGGTATCGTCGATGCCTCTCCCCCATCTTTAGAAAATTTGGCTCTTCTGAGGTCATTATTATTTTAAGAATGATTAGGATTGATAAGGGTCCCATGACCAGCATTATGAAAATGCGAGAGTGGGAAGGACACAGTGTGAGACTTCCACTAGAAAAAAGTGAAAGTTAGGGTTAGGACATCCTTTTTTAAAAATTACAAATTTAGTCCGTTTTGGTTTTTGTAATCAGGCTAGGCACAGTGGCTCACACATGGAATCCCAGCACTTTGGGAGGCCGAGGTGGGAGGATCACTTGAGCCCAGGAGTTCGAGACCAGCCTAGGCAACATAGCAAGACCCTGTCTGTACACAAAATTTAAAAATTAGTTCATCGGGGTGGCACACATCAGTAGTCCCAGCTACTCTGCAGGCTGAGGTGGGAGGATTGCTTGAACCCAGGAGGTCGAGGCTGCAGTGAGCTGTGATCTCACCACTGCATTCCAGCCTGGGTGACAGAGTTAGATTCCACCCTCTCCCACCCCGGCAAAAAAAAAAAAAAAAGATGCAATCAAAGGGGCTGTTGGCCAGCAATGGCAGCAGCAGCGGCGGGCAGTCTGCCCAAGTGTCTTAGGAACCAAAAGCAAATAAAAGTGTTTCCATATATGCCACCAGCCAAGTGGCCATCCTAATTCAGAAAGAAGCTAGCCTTTGAGTGTCTGTCATGGTGCATCCGTTTCAGTATTATTTCCTAAAATGAGAAGCCCCTGTGTCAACAAGATCCAGGGGCTGGAGCCCAATGCCAAGCCTGTGTTGTCCCCAGCGACCCTGCAGCTGCTCGCTCTGATGTACCCTGTGCCATTCAAGGAGATGTGGTCCAGGAAAGTGAGCCTCATGGTTTTCAGAGAAGTCATTGTTCTGTTTACATTTTCATAAAACCTGTTTAAAATAGCTCCCCGTCTCAGGCTTTCAGCAGTAACAGTGAGCTGACTGGCAAGTTCGATGTTAGCTCCCGGGACACTCAGCAGCGATGGTGAGCATTTTGGTTTCCTTAAGGCCCAGCAAGACTTCCAGGGACATCTCTGGTGAAGCCAGAATGGAGACACCCGTGACCTCAGGCTGAAAGTCACTCGACATTGGTCTCTTGTGTTGATAGGGAAGGAAATCAGGCATTCCTATTTCTTTAAATAACAAAACCACTAATTGCCACTCAATGCTGGAATATTTTGGGTCACCTAATCATAGATTTCTCAGGGCATCAATACTCAAATATAGGCTGATTATGCCCCAGTTCAAATGGGAACTATTAACAGAGTGCATTTCTTGCTTGCTGGGTTTCAACAGACATCAGCCAAAAGAACAAAAGAGATGTCAGGACAGATTCCAGGAGTGTCGGAGCACATGTGTGGCACCCGCTCCCTCTGGCAGCGAATGTAGGAAGTCGCCAAATTTACCCACTCTTCAACAAGTCATTGTTTAAACACGGTTTTTCATTTTCTCAACTTTTAATAGCAAAAAGTGCCAAAGTCCTCAGAGACCTAACAGCCTTGGTCTACCGTGCTGACCAGGGTGAAGGCACGGCGAGGGACTCCTCCCAGACGTGCCTCTTGTGTGCCAGCTGGCTGTGGCTCGGGAGCAGACGCAGGCCTCTCCATTGTCCAGGGGAGCCTGGCGGCGCATCCCTCCTCTCCCACCTCCTGGCACTTCCAGCTGGGTGTCCCACATGTTGGATTCCGTCCCCACCACACTTCCAGAGACCGGAGAACTGTGCAGGGCCTAAGGCCGTTTGGATGAATTGTCAAAACAAGATGCTTCCAGTTACAGCGGCAGGAGCGGGACTGGGAGCACGGGCTGACGGCTGCTGGTGCCTTTCTTCCCACCTCGCTTGCCTGTTTCCGCTTGACCCTTCCTCCAGCTCCGATGAGAAGAGTATAAAGCATCTTCCTAACGGGTGTGTTTGCTATACGAACATAATGGACGTGAAGTGGGGCAGAAACCCAGAACTCAGCATTCAAGGATGCCCAGGAGAGCTGTCCCTGTTTTAAAGAGCTGTGTTTTGTTTTGTTTCGCATTTAGAGAGCAGACAAGGCACCCTTCTGCTGCGCTGATACGTTTCTTACACTGGGCCATTTTAGACCCCCAGGGAAACAGCCTTCCTGGAGCGTTGTCTGGAGGTTCCAGGGACAGGGCAGCCTCCCAGAGCCGAGCAAGAGCTCAAGGTACAAATGAGAGATTTGCTATACCGTGAGAAGTCAACAACTTAGCCACCACTTCCCCGCAATGGACCATGTAACAAATACCTCAGCAGGCCCTGCAAAAGGCCATGCTAGAGCTGAGGCGCACAGCCTGTGGCCTCTGTAGTTAGGGCAGGTGGGATGGAGACTCCTTGAGTGCACACACCTGAGCCTGCCCACACACAGGGGAGCAGCATCTCGTATGACGTCTGGAAGGAACTTCGGTTGTGTAAAGGGAGCCTTGAAGATACGTGCAAAAGGTGCTACCCCAATTTGGTGAAACTGACATTGGGCACGTCTTGGGCTTAGGAGAAGCGGCCGATGGTCCCGGCCTGCAGTGACAAACCCCCCTCCCCGCACCGCCCCCAGCACCCCCTCTCCTCTTCACCTCTTCCTGCTGGCCACGAGGAAGCCACTTCCTCAGAGAGACCCTACCAGATGCGGATGGAAACAGATGCACCAAAGCAAGCCCTGATGAAACCGCGACTTCCTAAGGTCTGTCTCCTCTGAACTTGCACCTGGGCCTCTCTGTGTTTGGTTCCAAGCACTTCCCACCTCAAACTCCCATTTTCAAACCACTGTATCTCTGCGCACATCTGCTACTTACCAGCCGCATACATGATGGAGGGTTTTTTGGTCCTGATCCAGTGGCCACACCTGTCTTTGAAATGTCTCACTGAACTCCAGTTTTAAAATAGATTCATTGCTTCAACACAGCAAGCCCAATGCACCCAGCTAAGACTGGCTTGACCGACAGCCTGGCCTTTGGTGGGGGGCTTCCTGGGGCCTGGGGAAAGCTGGCCACCTTCAACAGCTGGTACCTCTTCAACAGTGTGGCCTTTCAAAATGCAGATGCCACCAGGAGAACATGCCCACAGCTCACCACCTATGGATGCCATGGCTCTGGGCAGCTTTCAAAGCAGGTTCCTGTGGTCTCCTCAGCTGTTTGAGGGGGTAACAGCAAATCAGCCTCCATTTTAAAATGAAAACACCAGCCTCCAGATGTAGGGCCTGCTGGGTGTTGCTAGCCGCTGGTCCCCAGGCACGGTGCACTTTCTCCACCTCCTGCAGCCTCCCTGTTGTTTCTAGACTCTTGCACCTGGTGAGTGCAAGGATAGGTGACCCAGGGGCCTGCAGCCTTGTCCTCAGCTCCCATCTCCTGGACTGCCAGCCTCACCCTCTGCAGTTAGCATGGTTGGCCTGATGCAGGGATCCCGAGGGATTACTTTTTAGACCTTCTTTCACATTCAGAAAAGTAGTATAGATTCAGGAGAGGCAAGAAAATTATGCTGTCCATAGAAGTCACCCATGAAGACTGATGCCACCACCTGAAGGCTCATGATTGTTAAAAATGTCCACGGGAACCTCTCGTCCACAGGAGGTTTGTCTCAACACTTCCCATTTTTACGGCATTGGCATTGCCAAGCATGGGGAAGTATCTGCTCTTCTCATGTTAAAAGTGGCCCAGCTTTTCTTAACTCAGTCCAAGCTGACTTGTTTAGCTGCACTGGAATTTCTTACCAACCAAATATTTGCATCGAGCAAAGGGGGCTGTGTGCACCTCCCTAATGGCAGCGATGATGGCTGCTGTCATTCAAGCCCATCTTCAGACGTCACAGTCTGGAAGTGAAATGTCCACAAACATCTGTGGCAGAAAAGGCTATACGGACCACCCAGTTGTGCTGCAGCTTTACAGAGCAAGGAAGGGTTGTGGCAAATAAATGATTAACCTGCCTCGACTGTGCTGAGGGCAACAAAGGCCATCTCACCAAAGGATTATTCGATGCCATTAAATCATCCCGTGACCTTCCTGCTTCCGAGTCCATGGCCTTTGCCCAGGGCATGTACTCCCCTGAGAGGCCTTCTGCCTAGAAAGATCTATGACTGGGTTCCAAAGTTGAGGCCTAGGTTTTTGCTGGGATTTAGATATTTTCAGGCACCATTTTGACAGCATTCAGGAAAACGGTTATTGACCCCATAGACTAGGGTAAGAATAAAGGCAATAAATTTGGTCTGACTCAGAATATAGGAGATCCATATATTTCTCTGGAAACCACAGTGTACACTAAAATGTGAAATTGAAGGTTTTGTTAAAAAGAAAAAGATAATGAGCTTCATGCTTTGTTTAATTACATAATGATTTCCATTACGCTATTTCTGTGAAATGCAGCAGGTTCTTAAACGTTATTTCAGTGGCATGGGCTGGAAGCTTATCACAAAAAGCCATGTGTGTGGCCTTATCAGAACAGAAAGAGACAGGCTGGTGCCCAAGGCTGCTGCCTGCTCCACCTTTTGCCAGCTCTGGACATCTGAGGACGTCCCGGCAGATCTGGAATGGGGCCCTCAACTGACCATTTGCTTCTCAGAATTTCAGTTTGAGACATGAGAGGTATAATCAGTTACTTTTCTCCCCCCAGAGAAACCCTTTTGTGAGGGGAGAGGAGCTATGGTATGTGGTTCAGCTGAAACACATACAACTGCATCCTTTTGGAGTCCTTTGCCAACAAAAACAGACCAACAGACCAGATGGTGTCCATGTTCAATATCATGTCTTGATGGACGCAGCTGATGACCTCAAATACTTGAGTGGTCTCATGGCTGTTAGATGGATTATTTGAAAAAAAAAAAAAAAAAAGAGAGAAAAAATAATTGATTTTTACATCAGAGATAGCAAACTAAGACCTGGGGAGGGGGGTCAGCTTTTATTTTATTTTATTTTTTTTAAGTTTGCTAGTTGGGTCAAATGTGAGGAGGAGGGAGTCTACCTGCCACCTCTTCTCTTGCCCCTCTTCTGCCCACACATCCAGCATCCAAAATCCATTCATTTAATGAATTGATAAAGTGCCGTGCAAACTGGTGCACAAACAGGCCCCCAGTCCACGCAGCCTGGCTCCTAGGAAAAGTGGTGACCGGGCGTGGGGGGGCATGCCGCAGCCCTGGGACACAGTCGGGCACCTTCCCCGGACCCCCAGGCCTTGGCTGTGCCTCAAGTCAGAGAGGGTCAGCCTTCAGGCCCCGGAGACGAGTGACTGGCCGATCATTTCACAATAAAATCACTCACTTTTGGCAACTTCACTTTTTTTAAGGCACAGTCAGTTCCTTTTCTCATGTACCTCACAAAAGATGAAGACCATGTAGTACTCTTTTTGGTAAAGTTACAGTGTTCATGTTAAATATCACTTTTTTCTACATTGTGTGGTAAAAAGAACTACGTTAATAGCTATATCTTAAATACTGTGATTTGACTTTTTGAAAAATATCCTAATACAAATATTTTACTAACTTACAATCACTCATTTAATAAGAAACATTTGGATTCTTTTGAAATCAGTGTTAATTGACTCATATTCTTAAAAGCCTGGCTCTTGACCCTATTGGAAACACAAAGGAAGCTGAAATCAAACATCTAAAATACACTGCGTACACGTGTGCGTGCACACACACACACACACACACACACACACAGCTCTTCATTTCTCCTGAGCCATGCAGAATTTACTTTCAATGTGGAAATCTGTTCCCTTTACCACACTGTATATGCACAGAGCACAAGAGAGGCTATCTCTAGTCACTTCCACCAGCGAGGCCTTAGACTCCGTATTAGAGGCCACCGATTTCATACAACAGTGTTTCGCTAAAGACCCTTCACTATTCTTGTTTAGTAAATAGCTGTCTGCTCTTCAGGGAACTGTTACCTATGGGTTATTACCAAAGAACGCTGGCAATTGGAAATGTCCTGATGGAAATTCTTTGCACGTGCCGGTTCTCTGGCATCCTCCAGGTGGCCCAACCCAAAGCAGAAAGCAGAAACCACAGACCCCGTGAGTCTCCCCATACCTTGTTTCCAATAACTTGGCAAAACTTCTTGGTGCATATTGGTTACACCCTCTGGGATTCATAATGCCATTAGGCTAAAACCCTAAGAGAGAGGGTTGACAGAAACACACGCGAGAATGAGGCAGATCCCAGAGCAAGGACTGGGCCCAGACTCTCCACATGTGCTCTACTAGTGAGTGCCTTATACTCTCAGTATTTTGGGGCTTACAGCTTCTTATTTGTGCTAAAAAGGTGCAGTTCCAAAGTAGGAACTGCCACACAGGCCCCAGCATCCTCTCTCCAACTTCATACCTCTCTCCTGGTGGGGGGAGCGGGCATCCAGGACCTCCGGAATCAAGGATGTGCAGAGAAGAGCGAAAGTAATTTTTCTAGTCACATGAACTGATTGGTTCCAGGCAATTAGAAAATGGCTATAAAATAACCTTAATTTTAAAAAAAAATCTTGGGTCTTCGTTTTCCTATTAGGAGACTGAACTGACCACATGTATTGATTTATATCCTGAATATATGGGAACTTCTGTGTTTGGGATGTCCTACTGTAAGACTGATGAATGTACAGAGTTAATTTCAGGGTACAGTTTTGCCTTAATGGTTTTAAAAAATAAACTATTTTTTAAAATTTT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PPARA</Gene_Name>
    <Gene_Alias>NR1C1; PPAR</Gene_Alias>
    <Gene_ID>5465</Gene_ID>
    <Genbank_ACCN>NM_001001928</Genbank_ACCN>
    <Protein_ACCN>NP_001001928</Protein_ACCN>
    <HGNC_ID>9232</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5465</Gene_URL>
    <UCSC_ID>uc003bgw.1</UCSC_ID>
    <EMBL_ID>ENSG00000186951</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q3L8U1-3</Uniprot_ID>
      <Gene_Name>CHD9</Gene_Name>
      <EBI_ID>EBI-960730</EBI_ID>
      <PPI_EBI_URL>EBI-78615,EBI-960730</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alcoholic Cardiomyopathy</Disease_Name>
      <Disease_Detail>Alcoholic Cardiomyopathy</Disease_Detail>
      <Disease_DB>ALC010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alcoholic_cardiomyopathy?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoalphalipoproteinemia</Disease_Name>
      <Disease_Detail>Hypoalphalipoproteinemia</Disease_Detail>
      <Disease_DB>HYP121</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoalphalipoproteinemia?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tularemia</Disease_Name>
      <Disease_Detail>Tularemia</Disease_Detail>
      <Disease_DB>TLR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tularemia?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fatty Acid Oxidation Disorders</Disease_Name>
      <Disease_Detail>Fatty Acid Oxidation Disorders</Disease_Detail>
      <Disease_DB>FTT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fatty_acid_oxidation_disorders?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperapobetalipoproteinemia</Disease_Name>
      <Disease_Detail>Hyperapobetalipoproteinemia</Disease_Detail>
      <Disease_DB>HYP456</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperapobetalipoproteinemia?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance?search=PPARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertensive Heart Disease</Disease_Name>
      <Disease_Detail>Hypertensive Heart Disease</Disease_Detail>
      <Disease_DB>HYP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertensive_heart_disease?search=PPARA#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid</PDB_Title>
      <PDB_ID>3ET1</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ET1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</PubMed_Title>
      <Author>Artis, D.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:262-267</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19116277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design and biological evaluation of novel, balanced dual PPARa/g agonists</PDB_Title>
      <PDB_ID>3FEI</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FEI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists</PubMed_Title>
      <Author>Grether, U., et al.</Author>
      <Journal>Chemmedchem(2009)4:951-956</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19326383?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242</PDB_Title>
      <PDB_ID>1I7G</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1I7G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.</PubMed_Title>
      <Author>Cronet, P., et al.</Author>
      <Journal>Structure(2001)9:699-706</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11587644?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>a crystal structure of PPAR alpha bound with SRC1 peptide and GW735</PDB_Title>
      <PDB_ID>2P54</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P54</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPAR Agonists. 1.Discovery of a Novel Series of Potent HDLc Raising Agents.</PubMed_Title>
      <Author>Sierra, M.L., et al.</Author>
      <Journal>J.Med.Chem.(2007)50:685-695</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17243659?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((2-(4-Chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-N-((4-methylphenoxy)carbonyl)glycine</PDB_Title>
      <PDB_ID>3KDU</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KDU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).</PubMed_Title>
      <Author>Li, J., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:2854-2864</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20218621?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>the crystal structure of the human PPARaplpha ligand binding domain in complex with a a-hydroxyimino phenylpropanoic acid</PDB_Title>
      <PDB_ID>2NPA</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2NPA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists</PubMed_Title>
      <Author>Han, H.O., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:937-941</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17157019?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human PPAR-alpha ligand-binding domain in complex with an antagonist GW6471 and a SMRT corepressor motif</PDB_Title>
      <PDB_ID>1KKQ</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KKQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha.</PubMed_Title>
      <Author>Xu, H.E., et al.</Author>
      <Journal>Nature(2002)415:813-817</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11845213?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The 2.5 Angstrom resolution crystal structure of the human PPARalpha ligand binding domain bound with GW409544 and a co-activator peptide.</PDB_Title>
      <PDB_ID>1K7L</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K7L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.</PubMed_Title>
      <Author>Xu, H.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2001)98:13919-13924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11698662?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes</PDB_Title>
      <PDB_ID>3G8I</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G8I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.</PubMed_Title>
      <Author>Benardeau, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2468-2473</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19349176?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPRR alpha ligand binding domain in complex with a synthetic agonist TIPP703</PDB_Title>
      <PDB_ID>2ZNN</PDB_ID>
      <Resolution>2.01</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZNN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures</PubMed_Title>
      <Author>Oyama, T., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2009)65:786-795</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19622862?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARalpha ligand binding domain with BMS-631707</PDB_Title>
      <PDB_ID>2REW</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2REW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of Azetidinone Acids as Conformationally-Constrained Dual (alpha/gamma) PPAR Activators</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((2-(4-Chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-N-(methoxycarbonyl)glycine</PDB_Title>
      <PDB_ID>3KDT</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).</PubMed_Title>
      <Author>Li, J., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:2854-2864</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20218621?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for iloprost as a dual PPARalpha/delta agonist</PDB_Title>
      <PDB_ID>3SP6</PDB_ID>
      <Resolution>2.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SP6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for iloprost as a dual PPARalpha/delta agonist</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04920</Pathway_ID>
      <Pathway_Title>Adipocytokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04024</Pathway_ID>
      <Pathway_Title>cAMP signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04922</Pathway_ID>
      <Pathway_Title>Glucagon signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.bg.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1i7g</CATH_URL>
  </Fold>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>